Cerenome (PSTV) Receivables (2010 - 2026)

Plus Therapeutics (PSTV) posted quarterly Receivables of $1.3 million for Q1 2026, up 319.25% quarter-over-quarter from $322000.0 in Q4 2025.

Cerenome (PSTV) Receivables (2010 - 2026) Analysis & Trends

Plus Therapeutics (PSTV) has reported Receivables for 16 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.

In Q1 2026, Receivables changed N/A year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (changed N/A YoY), while the FY2025 annual figure was $322000.0, down 43.61% from the prior year.
Receivables rose to $1.3 million in Q1 2026 per PSTV's latest filing, from $322000.0 in the prior quarter.
Across five years, Receivables topped out at $1.3 million in Q1 2026 and bottomed at $73000.0 in Q3 2022.
Historically, Receivables has averaged $592285.7 across 5 years, with a median of $571000.0 in 2024.
Annual changes were most pronounced in 2023 — Receivables climbed 24.66% — and 2025, when it plunged 43.61%.
Plus Therapeutics' Receivables stood at $73000.0 in 2022, then climbed by 24.66% to $91000.0 in 2023, then surged by 527.47% to $571000.0 in 2024, then slumped by 43.61% to $322000.0 in 2025, then jumped by 319.25% to $1.3 million in 2026.
Business Quant data shows PSTV's Receivables at $1.3 million in Q1 2026, $322000.0 in Q4 2025, and $1.0 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	139.81 Bn	131.96 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	86.56 Bn	78.56 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	65.72 Bn	60.53 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.75 Bn	53.61 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.76 Bn	28.45 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	28.59 Bn	10.19 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.63 Bn	26.47 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.24 Bn	26.40 Bn	-	-
10	Cerenome	28.07 Mn	19.48 Mn	-	-

Download Data